Asthma and Co-morbid Conditions:
Expanding the Practice of Allergy for Optimal Patient Care

5 – 8 DECEMBER 2010
Dubai International Convention and Exhibition Centre
DUBAI, UAE

www.worldallergy.org/2010Dubai
ABOUT WAO

The World Allergy Organization (WAO) is an international umbrella organization consisting of 84 regional and national allergy, asthma and clinical immunology societies from around the world. By collaborating with its member societies, WAO provides direct educational and outreach programs to members in nearly 100 countries.

WAO was founded in 1951 and has successfully organized 21 major congresses. WAO also sponsors scientific symposia and allergy training schools in emerging societies, and jointly sponsors postgraduate programs on allergy, asthma and clinical immunology during professional medical congresses.

As a global federation, WAO provides active services and support to its member societies.

WAO’S MISSION

To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

WAO BOARD OF DIRECTORS

2010-2011

Richard F. Lockey, President
Mario Sánchez Borges, Treasurer
Lanny Rosenwasser, Secretary-General
Ruby Pawankar, President-Elect
G. Walter Canonica, Past-President
Michael A. Kaliner, Historian
Ignacio Ansotegui
Michael Blaiss
Thomas B. Casale
Motohiro Ebisawa
Yehia El-Gamal
Sandra González-Díaz
Tari Haatela
Stephen T. Holgate
Juan Carlos Ivancevich
Marek Kowalski
Hae-Sim Park
Paul Potter
Tatiana Slavyanskaya
Myron Zitt

CONGRESS WEBSITE

www.worldallergy.org/2010Dubai

IMPORTANT ADDRESSES

WAO Secretariat
555 East Wells Street, Suite 1100
Milwaukee, WI 53202, USA
Phone: +1 414 276 1791
Fax: +1 414 276 3349

General Inquiries
WISC2010@worldallergy.org

Registration
WISC2010registration@worldallergy.org

Abstracts
WISC2010abstracts@worldallergy.org

Exhibition
WISC2010exhibition@worldallergy.org

Local Professional Congress Organizer
MCI Middle East
www.mci-group.com

CONTENTS PAGE

Invitation ............................................. 3
Committees ........................................... 3
Conference Information .................. 4
Program-At-A-Glance ...................... 5–8
Scientific Program ......................... 9–23
Call for Abstracts ......................... 24–25
Registration ..................................... 26
Social Program ................................ 27
Optional Tours ................................. 27–29
Accommodation ............................. 29
General Information ....................... 30–31
Sponsors ................................. Back cover

IMPORTANT DATES

16 July 2010
Abstract Submission Deadline

16 July 2010
Early Registration Deadline

1 September 2010
Accommodation Reservation Deadline

31 October 2010
Late Registration Deadline

4 December 2010
Onsite Registration Begins

5–8 December 2010
1st WAO International Scientific Conference
INVITATION TO PARTICIPATE

Dear Colleagues,

It is with great pleasure that we invite you to participate in the 1st WAO International Scientific Conference. This inaugural WAO International Scientific Conference will focus on Asthma and Co-morbid Conditions: Expanding the Practice of Allergy for Optimal Patient Care and will be held from 5 - 8 December 2010 in Dubai, UAE.

WAO is excited to launch its theme-based scientific conferences alternating with and complementing WAO’s biennial World Allergy Congress.

WAO introduces these focused, theme-based scientific conferences in recognition of:

- The growing burden of asthma & allergy worldwide
- The increasing awareness of asthma and allergy as global public health concerns
- The need to expand the practice of allergy for optimal patient care
- The new member societies WAO welcomes every year

The 2010 meeting on Asthma and Co-morbid Conditions will provide a forum for the latest research, reviews of current theory and practice, and hands-on, problem-based learning. Participants will gain insight into the most effective advances in the diagnosis and management of asthma and its co-morbidities.

We look forward to seeing you in Dubai!

On behalf of the WAO Board of Directors,

Richard F. Lockey
WAO President
Conference President

Ruby Pawankar
WAO President-Elect
Conference Organizing Chair

G. Walter Canonica
WAO Past-President
Executive Chair, Scientific Program Committee

CONFERENCE PRESIDENT
Richard F. Lockey

CONFERENCE ORGANIZING CHAIR
Ruby Pawankar

SCIENTIFIC PROGRAM COMMITTEE
G. Walter Canonica, Executive Chair
Eric Bateman, Co-Chair
Stephen T. Holgate, Co-Chair
Robert Lemanske, Co-Chair

LOCAL ORGANIZING COMMITTEE
Ruby Pawankar, Chair
Bassam Mahboub, Co-Chair
Mona Al Ahmad, Co-Chair
Suleiman Al Hammadi
Saleh Al Muhsen
Salem Al Tamemi
Abdulla Ibrahim

REGIONAL ADVISOR
Yehia El-Gamal

REGIONAL ADVISORY COMMITTEE
Hani Ababneh
Malek Abdulalim
Yousef Abdulrazzaq
Abdulrahman Al Frayh
Harb Al Harfi
Jamil Al Mughales
Mirza Al Sayegh
Adel Al Wahadneh
Shirina Al Souwaidi
Zeinab Awad
Zeina Baz
Abdenour Benyounes
Habib Douagui
Mohamad Ehlayed
Ahmed Elbousify
Youness El Gueddari
Kamal Hanna
Syed Hasnain
Elham Hossny
Lubna Hwejeh
Omer Kalayci
Ali Ben Kheder
Andreas Liveris
Yousser Mohamed
Mostafa Moin
Mohammad Reza Masjedi
Menachem Rottem
Fadhel Saleh
Zineb Sayah
Arzu Yorgancioglu
Fares Zaitoun
CONFERENCE INFORMATION

OBJECTIVES
• To provide insight into the fundamentals of asthma and its co-morbidities
• To highlight the most recent advances and developments in asthma and co-morbidities
• To develop a consensus on scientifically-based medicine for each co-morbid condition as it relates to asthma
• To identify unmet needs and areas of research priorities

WHO WILL ATTEND?
The conference will be attended by delegates from all over the world. Delegates will be researchers, clinicians, physicians and other allied health professionals with interests in:

- Allergy
- Asthma
- Co-morbid Conditions
- Dermatology
- ENT
- Immunology
- Ophthalmology
- Pediatrics
- Pulmonology

KEY REASONS TO ATTEND
Be on the leading edge of medical learning & education!
• Attend State of the Art lectures by the “Who’s Who” in the global field of allergy, asthma and co-morbidities.
• Participate in practical, clinic-friendly workshops on food allergy, asthma, spirometry, rhinoscopy, bronchoscopy, immunotherapy, sleep apnea, and more.
• Network with others in your field and areas of interest.
• Receive CME credits.
• Showcase your achievements to key international opinion leaders.

CME
Approval of the scientific program for continuing medical education (CME) credits will be applied for with the European Accreditation Council for Continuing Medical Education (EACCME). The EACCME is an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognized by the American Medical Association (AMA).

More information regarding CME, including local CME (UAE), will be available closer to the dates of the meeting. Please visit www.worldallergy.org/2010Dubai for frequent updates.

CERTIFICATES OF ATTENDANCE
Certificates of Attendance will be provided to all conference registrants.

SESSION DESCRIPTIONS

Plenary Sessions
Plenary presentations will set the stage with context and background through overviews and literature reviews to define unmet needs.

Symposia
Symposia will address specific topics, providing the opportunity for in-depth and detailed exploration.

Postgraduate Courses
Postgraduate Courses will be oriented toward the clinic, have a less formal approach and be more participatory.

Keynote Lunch Symposia
Keynote Lunch Symposia offer attendees the opportunity to attend a 20-minute lecture on a specific topic from one of the key opinion leaders in the field. Lunch boxes will be available for all attendees.

Poster Sessions
Accepted abstracts will be presented during Poster Sessions. Presenting Authors will stand with their posters, answer questions and discuss their research.
<table>
<thead>
<tr>
<th>Time</th>
<th>Postgraduate Course: Spirometry</th>
<th>Postgraduate Course: Nasal endoscopy and challenge tests</th>
<th>Postgraduate Course: CPAP and sleep disorders</th>
<th>Postgraduate Course: Sputum analysis / BAL analysis</th>
<th>Postgraduate Course: Managing smoking cessation clinics</th>
<th>Postgraduate Course: Aspirin desensitization</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Coffee Break**

**Lunch Break**

**Coffee Break**

**Opening Ceremony**

**Welcome Reception**
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>Plenary Session: Update on asthma and lower airway co-morbidities</td>
</tr>
<tr>
<td>7:15</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>7:30</td>
<td>Symposium: Update on asthma research and clinical practice</td>
</tr>
<tr>
<td>7:45</td>
<td>Symposium: Asthma and co-morbidities</td>
</tr>
<tr>
<td>8:00</td>
<td>Symposium: Asthma in the elderly</td>
</tr>
<tr>
<td>8:15</td>
<td>Presidential Keynote Lunch Symposium: Asthma and co-morbid conditions</td>
</tr>
<tr>
<td>8:30</td>
<td>Plenary Session: Asthma &amp; upper airway co-morbidities</td>
</tr>
<tr>
<td>8:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>9:00</td>
<td>Symposium: Asthma and upper airway co-morbidities 1: Research and clinical practice updates</td>
</tr>
<tr>
<td>9:15</td>
<td>Symposium: Asthma and upper airway co-morbidities 2: Looking ahead</td>
</tr>
<tr>
<td>9:30</td>
<td>Symposium: Asthma and upper airway co-morbidities in the Gulf and Near East</td>
</tr>
<tr>
<td>9:45</td>
<td>Poster Viewing and Networking Session with Faculty and the WAO Leadership</td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:00</td>
<td></td>
</tr>
<tr>
<td>7:15</td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
</tr>
<tr>
<td>7:45</td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
</tr>
</tbody>
</table>
## PROGRAM-AT-A-GLANCE

### Wednesday, 8 December 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>Plenary Session:</td>
</tr>
<tr>
<td>7:15</td>
<td>Asthma and atopic eczema, food allergy, anaphylaxis</td>
</tr>
<tr>
<td>8:00</td>
<td>Plenary Session:</td>
</tr>
<tr>
<td>8:15</td>
<td>Poster Session</td>
</tr>
<tr>
<td>8:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>9:00</td>
<td>Symposium:</td>
</tr>
<tr>
<td>9:15</td>
<td>Asthma and concomitant chest diseases</td>
</tr>
<tr>
<td>9:45</td>
<td>Symposium:</td>
</tr>
<tr>
<td>10:00</td>
<td>Asthma and viral infections</td>
</tr>
<tr>
<td>10:15</td>
<td>Symposium:</td>
</tr>
<tr>
<td>10:30</td>
<td>Asthma and chest co-morbidities in the Middle East</td>
</tr>
<tr>
<td>11:00</td>
<td>Keynote Lunch Symposium:</td>
</tr>
<tr>
<td>11:15</td>
<td>Asthma and immunotherapy – Past, present and future</td>
</tr>
<tr>
<td>12:00</td>
<td>Plenary Session:</td>
</tr>
<tr>
<td>13:00</td>
<td>Asthma and COPD: Present and future therapies</td>
</tr>
</tbody>
</table>

---

**FOR MORE INFORMATION ON OTHER WAO INITIATIVES INCLUDING:**

- World Allergy Organization Journal
- Online Learning
- Allergic Diseases Resource Center
- World Allergy Forum
- Emerging Societies Program
- World Allergy Congress

**GO TO WAO ONLINE AT**

[www.worldallergy.org](http://www.worldallergy.org)
### Postgraduate Courses—Sunday, 5 December 2010

**Postgraduate courses are included in the registration fee; however, pre-registration is required. Attendance is limited in a number of courses.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course</th>
<th>Learning Objectives</th>
<th>Speakers</th>
<th>Attendance</th>
</tr>
</thead>
</table>
| 9:00 – 10:30 | **PG1 Spirometry** | - To define what constitutes accurate and adequate spirometric assessment  
- To discuss how spirometry performance and interpretation differ depending on age  
- To review how pulmonary function assessment compares with other outcome measures in asthma | Omar Al Rawas, Thomas B. Casale, Stephen Peters | Limited to 50 persons |
|  | **PG2 Nasal endoscopy and challenge tests** | - To demonstrate how to use these practical procedures to yield reproducible results  
- To show how to assess the outcomes of these tests and best use them in the clinic  
- To explain when to opt for a challenge test | Abdulla Ibrahim, Dennis Ledford, Ruby Pawankar | Limited to 50 persons |
|  | **PG3 CPAP and sleep disorders** | - To explain better the physiology and pathophysiology of obstructive sleep apnea and its consequences  
- To emphasize the magnitude of the clinical problem  
- To make familiar the practical aspects of treatment techniques  
- To identify unmet needs | Fulvio Braido, TBA | Limited to 50 persons |
|  | **PG4 Sputum analysis / BAL analysis** | - To explain the advantages and disadvantages of sputum versus BAL analyses  
- To present data regarding what biomarkers in either sputum or BAL may be useful for clinical monitoring  
- To discuss the age groups in which sputum induction can be performed and interpreted | Neil Barnes, Louis-Philippe Boulet, Paul O’Byrne | |
|  | **PG5 Managing smoking cessation clinics** | - To review best practices on how and where to set up such clinics  
- To discuss what management approaches work best and why  
- To discuss effective ways to ensure adherence to non-smoking | Bassam Mahboub, Riccardo Polosa, Giovanni Viegi | |
|  | **PG6 Aspirin desensitization** | - To understand the principles of aspirin desensitization  
- To demonstrate how to assess correctly when is it indicated  
- To review the mechanisms of aspirin desensitization and what are its short and long-term outcomes | Marek Kowalski, Hae-Sim Park | |
| 11:00 – 12:30 | **PG7 Investigating and managing upper airway disorders** | - To demonstrate upper airway disorders examination techniques, including rhinolaryngoscopy  
- To illustrate upper airway disorder’s common pathologies, including the causes of sleep-disordered breathing | G. Walter Canonica, Omer Kalayci, Michael A. Kaliner | Limited to 50 persons |
|  | **PG8 Exhaled NO and other markers of inflammation** | - To show how NO works as a mediator in inflammation  
- To show how to measure accurately NO in exhaled breath and its significance  
- To review the clinical applications of exhaled NO measures | Myron Zitt, Riccardo Polosa | Limited to 50 persons |
### PG 9 Inhalation devices

**Learning Objectives:**
- To review various asthma medication delivery systems relevant to age
- To show how HFA propellants may affect drug delivery from MDIs
- To provide insight into spacers and their importance in drug delivery

**Speakers:**
- Suleiman Al Hammadi
- Juan Carlos Ivancevich
- Paul O’Byrne

*Attendance: Limited to 60 persons*

### PG 10 Dietary factors and weight management

**Learning Objectives:**
- To review appropriate dietary management in preschool children
- To provide updates on the use of probiotics in disease prevention
- To present information regarding what dietary and/or behavioral interventions are most successful in achieving appropriate weight control

**Speakers:**
- Michael Blaiss
- Paul Greenberger

### PG 11 Asthma self-management (SM) plans

**Learning Objectives:**
- To emphasize the importance of patient self-management plans for asthma
- To provide examples of SM plans for use in children, adolescents and adults, in different practice settings
- To review the impact of illiteracy, resource limitation and other barriers to self-management

**Speakers:**
- Ignacio Ansotegui
- Tari Haahlela
- Menachem Rottem

### PG 12 Clinical methods for distinguishing COPD and asthma

**Learning Objectives:**
- To review different methods for distinguishing asthma from COPD in different practice settings, including the role of screening questionnaires, lung function and allergy tests
- To review and discuss the role of clinical trials of therapy and monitoring of outcomes in asthma/COPD

**Speakers:**
- Hatem Al Ameri
- Eric Bateman
- Stephen Peters

### PG 13 Practical aspects of managing rhinitis and asthma in children

**Learning Objectives:**
- To explain the process of diagnosis of rhinitis and asthma in children
- To make familiar the specifics of treatment of rhinitis and asthma in children, especially in relation to safety, efficacy and easy administration for better compliance in pediatric populations
- To identify specifics that may be related to region

**Speakers:**
- Salem Al Tamemi
- Carlos E. Baena-Cagnani
- Michael Blaiss

*Attendance: Limited to 50 persons*

### PG 14 Food challenge test

**Learning Objectives:**
- To review the role of challenge testing in the diagnosis of food allergy by skin or blood testing
- To show the respiratory tract as a target and route for food allergy
- To review the spectrum of erythema multiforme / Stevens-Johnson syndrome / toxic epidermal necrolysis

**Speakers:**
- Sami Bahna
- Motohiro Ebisawa
- Alessandro Fiocchi

*Attendance: Limited to 50 persons*

### PG 15 Optimizing asthma management and treatment through behavior modification

**Learning Objectives:**
- To provide insight into reasons for non-compliance in asthma therapy, including patient fears
- To review effective ways of enhancing treatment compliance at different ages

**Speakers:**
- Fulvio Braido
- Harold Nelson
- Mario Sánchez-Borges

### PG 16 Role of bone scanning in asthma and osteoporosis

**Learning Objectives:**
- To review the different methods used to assess bone density
- To review the risks and benefits of bone density assessments

**Speakers:**
- Dennis Ledford
- Richard F. Lockey
PG 17 Managing chronic cough

Learning Objective:
• To demonstrate the combined diagnostic/therapeutic approach to chronic cough

Speakers: Pramod Kelkar
          Riccardo Polosa

PG 18 Asthma control measures in research and clinical practice

Learning Objectives:
• To review and compare validated measures for assessing asthma control
• To provide practical advice on their use in clinical research and in various clinical care settings
• To show the relationship between current control and “future” risk and its implications for care and for setting treatment goals

Speakers: Sergio Bonini
          Paul O’Byrne

PG 19 When and how to use epinephrine / Treatment of anaphylaxis

Learning Objectives:
• To review the mechanisms by which epinephrine reduces the symptoms of anaphylaxis
• To present appropriate dosing and route of administration of epinephrine
• To discuss when epinephrine should or should not be given to school children with histories of “anaphylaxis”

Speakers: Richard F. Lockey
          Myron Zitt

Attendance: Limited to 50 persons

PG 20 Skin testing: Theory and practice

Learning Objectives:
• To review the use of skin testing for allergy
• To review the approved methods of skin testing
• To discuss ways to improve skin testing, such as use of recombinant allergens

Speakers: Sami Bahna
          Sandra González-Díaz
          Fares Zaltoun

Attendance: Limited to 50 persons

PG 21 Bronchial provocation tests in adults and children

Learning Objectives:
• To describe different forms of bronchial provocation tests and their uses
• To provide practical advice on their selection and conduct
• To review the safety and interpretation of bronchial provocation tests

Speakers: Riccardo Polosa
          Giovanni Viegi

PG 22 Preventing asthma exacerbations

Learning Objectives:
• To address the question: What defines an asthma exacerbation versus loss of asthma control
• To discuss which patients may be at increased risk for exacerbations
• To review why reducing exacerbation frequency may be important in terms of long term consequences (i.e., loss of lung function)

Speakers: Thomas B. Casale
          Nizar Kheralla
          Marek Kowalski

PG 23 Asthma education

Learning Objectives:
• To review the definitions of asthma severity and control
• To reinforce the concepts of current asthma impairment versus future asthma risk
• To indentify barriers in communication that impair both short and long term asthma education

Speakers: Tari Haahtela
          Michael A. Kaliner
          Tatiana Slavyanskaya

PG 24 Practical aspects of immunotherapy

Learning Objectives:
• To review the process of how to select patients for immunotherapy
• To explain the methodology of immunotherapy and who should administer it to the patient
• To review the risks and benefits of the different types of immunotherapy

Speakers: G. Walter Canonica
          Harold Nelson
PS1 Plenary: Update on asthma and lower airway co-morbidities

**Learning Objectives:**
- To provide an overview of recent advances in asthma pathophysiology and treatment
- To show the relationship of lower airway co-morbidities to asthma severity and control
- To review new approaches to treatments directed toward lower airway co-morbidities

**08:00** Epidemiology and risk factors for asthma and COPD | Giovanni Viegi

**Learning Objectives:**
- To define which epidemiologic factors are unique to asthma and COPD and those that are shared
- To review the risk factors for the development of asthma and COPD
- To provide insight into treating patients with overlapping conditions

**08:25** Severe asthma in children | Lanny Rosenwasser

**Learning Objectives:**
- To identify the trigger factors for, and show the importance of, childhood asthma morbidity and mortality
- To explain the pathophysiology of severe asthma and its consequences in children
- To demonstrate how to identify predictors of severe asthma in children
- To review the treatment of severe asthma in children

**08:50** Pathophysiology and remodeling of asthma | Stephen T. Holgate

**Learning Objectives:**
- To describe what is meant by the term “remodeling”
- To explain when airway remodeling may begin and how it affects asthma severity and control over time
- To review therapeutic approaches for prevention and treatment of remodeling in asthma

**09:15** NHLBI: Asthma phenotypes | Richard F. Lockey

**Learning Objectives:**
- To review current definitions of various asthma phenotypes
- To present how the use of asthma phenotypes in clinical research trials may be useful
- To explain how phenotyping can be useful in asthma diagnosis and treatment

**09:40** Question & Answer

---

**10:30 – 12:00**

SY1 Symposium: Update on asthma research and clinical practice

**Learning Objectives:**
- To define asthma exacerbations and their relevance to future risk and impairment
- To explain the concept of asthma “control”
- To review various approaches for the recognition and treatment of difficult-to-control asthma

**10:30** Asthma control: Setting goals | Eric Bateman

**Learning Objectives:**
- To review current thinking on what defines acceptable asthma control
- To review tools that are available to evaluate control
- To review how two set goals to achieve asthma control

**10:50** Difficult-to-control asthma | Paul O’Byrne

**Learning Objectives:**
- To define what is difficult-to-control asthma
- To describe populations that may be at particular risk
- To review the natural history of difficult-to-control asthma

**11:10** Asthma exacerbation and reducing emergency room visits | Tari Haahtele

**Learning Objectives:**
- To review what constitutes an asthma exacerbation
- To describe common factors that trigger asthma exacerbations both in children and adults
- To explain how prevention of exacerbations may be relevant to loss of lung function over time

**11:30** Question & Answer
10:30 – 12:00 (continued)

SY2  Symposium: Asthma and co-morbidities
Learning Objectives:
• To review co-morbid conditions that may manifest as asthma
• To address the relationship between systemic disorders and asthma and its treatment
• To describe diagnostic implications

10:30  Asthma and rheumatic disorders and vasculitis  | Lanny Rosenwasser
Learning Objectives:
• To provide an understanding of other immunological conditions that manifest as asthma
• To show when to be suspicious of systemic causes
• To explain the relationship between the management of connective tissue and vasculitic disorders

10:50  Asthma and osteoporosis and osteopenia  | Dennis Ledford
Learning Objectives:
• To review the factors influencing bone density in allergic disease
• To explain the factors involved in inhaled corticosteroids and growth in children and osteoporosis in adults
• To describe how to manage bone and allied disorders in asthma

11:10  Asthma in the elite athlete  | Sergio Bonini
Learning Objectives:
• To show how to assess allergic diseases in athletes and their impact on sporting activity
• To describe the implications of exercise induced asthma in competitive sports individuals
• To review the prevention and management of allergic disease in competitive sports

11:30  Question & Answer

SY3  Symposium: Asthma in the elderly
Learning Objectives:
• To emphasize the importance and high prevalence of asthma in the elderly
• To consider clinical presentations and management issues of asthma in the elderly
• To consider diagnostic challenges presented by co-morbid conditions

10:30  Asthma and co-morbidities in the elderly  | Neil Barnes
Learning Objectives:
• To emphasize the importance and high prevalence of asthma in the elderly
• To consider clinical presentations of asthma and common co-morbidities, such as heart failure, diabetes, hypertension, GERD, and ways of assessing their relative contributions

10:50  Life-long asthma and its relationship to COPD  | Stephen T. Holgate
Learning Objectives:
• To review of the effects of life-long asthma in the elderly and how these differ from COPD
• To explore clinical and laboratory methods for distinguishing asthma from COPD

11:10  Overcoming gaps and optimizing management of asthma in the elderly  | Louis-Philippe Boulet
Learning Objectives:
• To consider the challenges in treating asthma in the elderly and ways of overcoming these challenges
• To review the setting of goals for asthma management and monitoring of outcomes in the elderly
• To consider the problems of drug interactions in the elderly with asthma

11:30  Question & Answer

12:00 – 13:00

KN1  Presidential Keynote Lunch Symposium: Asthma and co-morbid conditions
Learning Objectives:
• To provide an overview on the fundamentals of asthma and co-morbid conditions
• To review the scientific data which links asthma and co-morbid conditions
• To highlight the effective advances in the diagnosis and treatment of such conditions

Speaker: Richard F. Lockey
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Learning Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td><strong>Plenary: Asthma &amp; upper airway co-morbidities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and allergic rhinitis: The link</strong></td>
<td>Ruby Pawankar</td>
<td>• To explain the concept of “United Airways”</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and evidence-based management of allergic rhinitis</strong></td>
<td>G. Walter Canonica</td>
<td>• To review the epidemiology and pathophysiology of the upper airway</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and rhinosinusitis</strong></td>
<td>Michael A. Kaliner</td>
<td>• To review the epidemiology and clinical importance of rhinosinusitis</td>
</tr>
<tr>
<td></td>
<td><strong>Non-allergic rhinitis and asthma</strong></td>
<td>Glenis Scadding</td>
<td>• To clarify the classification and phenotypes of non-allergic rhinitis</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and nasal polyps</strong></td>
<td>Hae-Sim Park</td>
<td>• To explain the mechanisms of polyp formation and risk factors</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and aspirin sensitivity</strong></td>
<td>Marek Kowalski</td>
<td>• To explain the mechanisms of aspirin-intolerant asthma</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and upper airway co-morbidities 1: Research and clinical practice updates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Asthma, rhinosinusitis and otitis media with effusion</strong></td>
<td>Ruby Pawankar</td>
<td>• To provide an understanding of different types of disorders</td>
</tr>
<tr>
<td></td>
<td><strong>Practical aspects of managing asthma and rhinosinusitis in the clinic</strong></td>
<td>Michael A. Kaliner</td>
<td>• To emphasize the importance of obtaining a diagnosis</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and nasal polyps</strong></td>
<td>Hae-Sim Park</td>
<td>• To review the diagnosis of nasal polyposis</td>
</tr>
<tr>
<td></td>
<td><strong>Asthma and aspirin sensitivity</strong></td>
<td>Marek Kowalski</td>
<td>• To explain the proposed mechanisms of aspirin-intolerant asthma</td>
</tr>
</tbody>
</table>

**SY4 Symposium: Asthma and upper airway co-morbidities 1: Research and clinical practice updates**

- To provide insight into the significance of the one-airway mechanisms and reciprocal relationships between the upper and lower airway in asthma and COPD.
- To show the therapeutic implications of “United Airways”.
- To describe the differences between rhinitis and asthma/COPD.

- To provide knowledge of different types of disorders and underlying mechanisms.
- To review different approaches to diagnosis.
- To review approaches to the management of these disorders.

- To emphasize the importance of obtaining a clear diagnosis.
- To review the approaches to therapy, including severe disease.

- To explain the mechanisms of polyp formation including pathology and risk factors.
- To review the diagnosis of nasal polyposis.
- To review the treatment options and prevention of recurrence.

- To explain the proposed mechanisms of aspirin-intolerant asthma.
- To explain how to diagnose aspirin-intolerant asthma.
- To review the management of aspirin-intolerant asthma.

**Question & Answer**
### SY5 Symposium: Asthma and upper airway co-morbidities 2: Looking ahead

**Learning Objectives:**
- To review functional upper airway disorders and their relationship with asthma
- To consider the contribution of GERD to asthma morbidity
- To evaluate the relationship(s) between obstructive sleep apnea and asthma

#### 15:30 Asthma and vocal cord dysfunction  
*Dennis Ledford*

**Learning Objective:**
- To provide a review of functional upper airway disorders—their mechanisms, relationship with asthma, diagnosis, and management

#### 15:50 Asthma, GERD and laryngeal pharyngeal reflux (LPR)  
*Richard F. Lockey*

**Learning Objectives:**
- To provide a review of the epidemiology of GERD and its relationship with asthma
- To explain the mechanisms underlying GERD and LPR in the asthmatic
- To consider the occurrence of GERD and LPR in the asthmatics
- To provide a review of treatment for GERD and LPR in asthma

#### 16:10 Asthma and obstructive sleep apnea  
*Fulvio Braido*

**Learning Objectives:**
- To consider if there is a relationship between asthma and obstructive sleep apnea
- To review management approaches to disturbed sleep in asthma

#### 16:30 Question & Answer

### SY6 Symposium: Asthma and upper airway co-morbidities in the Gulf and Near East

**Learning Objective:**
- To provide an understanding of the regional perspectives of the genetics, clinical phenotypes, epidemiology, risk factors of asthma and comorbid upper airway disease

#### 15:30 Genetics of asthma  
*Saleh Al-Muhsen*

**Learning Objective:**
- To provide an understanding of the regional characteristics of genetics, clinical phenotypes and therapeutic responses of asthma and co-morbid allergies

#### 15:50 Triggers of childhood asthma  
*Zeina Baz*

**Learning Objective:**
- To provide an understanding of the regional triggers and risk factors of childhood asthma

#### 16:10 Asthma and rhinitis  
*Mona Al Ahmed*

**Learning Objective:**
- To review the epidemiology, risk factors of asthma and co-morbid allergic rhinitis

#### 16:30 Asthma and sleep disorders  
*Ashraf Alzaabi*

**Learning Objective:**
- To review the relationship between asthma and obstructive sleep apnea in the region and the management strategies

#### 16:50 Question & Answer

### 17:00 – 18:30

**Poster Viewing and Networking Session with Faculty and the WAO Leadership**

Junior delegates will have the opportunity to discuss and view posters in an informal setting, as well as network with Conference faculty and the WAO Leadership. Light refreshments will be served.

Included in registration fee for delegates, nurses, and students
SCIENTIFIC PROGRAM—TUESDAY, 7 DECEMBER 2010

8:00 – 10:00

PS3  Plenary: Asthma and endocrine co-morbidities
Learning Objectives:
• To describe endocrine factors related to obesity that may contribute to asthma pathophysiology
• To review how weight gain or loss may influence asthma severity and/or control
• To consider the effects of pregnancy on asthma control and approaches to treatment

08:00  Dietary factors, obesity and pediatric asthma | Paul Greenberger
Learning Objectives:
• To review how to differentiate between lack of conditioning in obese children from loss of asthma control
• To consider when weight gain in childhood is most likely to contribute to asthma expression
• To present information regarding what dietary factors may be productive in reducing asthma induction and severity

08:25  Asthma and obesity in adults | Dennis Ledford
Learning Objectives:
• To address the question: Does obesity cause asthma or are asthmatic patients more likely to become obese?
• To review how obesity may influence treatment choices in asthma
• To review whether or not weight loss improves asthma control

08:50  Asthma and pregnancy | Harold Nelson
Learning Objectives:
• To review how pregnancy may influence asthma control
• To review which treatments are safe to use during pregnancy
• To address the influence of parity status on asthma control and/or response to therapy

09:15  Gender and development of asthma | Robert Lemanske
Learning Objectives:
• To review gender differences with respect to asthma expression, remission, and progression
• To consider possible endocrinological mechanisms underlying asthma disease severity as it relates to gender
• To explain pulmonary physiologic alterations that differ by gender

09:40  Question & Answer

10:30 – 12:00

SY7  Symposium: An overview of pediatric asthma
Learning Objectives:
• To explain the contributions of allergic sensitization and viral infections to childhood wheezing and asthma
• To review what intervention strategies may be useful in preventing the development of allergies and asthma
• To review data as to when early childhood wheezing can be classified as asthma

10:30  Wheezing pre-asthma phenotypes in pre-school children | Robert Lemanske
Learning Objectives:
• To describe the various wheezing phenotypes and their relationship to asthma expression in later childhood
• To explain what factors are most influential in early life that predict asthma risk in school-aged children
• To consider the contribution of both genetic and environmental factors to childhood asthma

10:50  Asthma and allergies in school-age children and adolescents | Carlos E. Baena-Cagnani
Learning Objectives:
• To define the terms “atopic” and “allergic sensitization”
• To review at what age immediate hypersensitivity testing can be performed and interpreted
• To explain the contribution of aeroallergens to asthma pathogenesis

11:10  Prevention of pediatric asthma and allergies | Tari Haahtela
Learning Objectives:
• To review strategies for the prevention of allergic sensitization
• To discuss issues related to the use of probiotics
• To address what factors may be relevant to the prevention of asthma

11:30  Question & Answer
SCIENTIFIC PROGRAM—TUESDAY, 7 DECEMBER 2010

10:30 – 12:00 (continued)

SY8 Symposium: Asthma, endocrine disorders and iatrogenesis
Learning Objectives:
• To review the link, if any, between endocrine disorders and asthma
• To review the management of thyrotoxicosis in asthmatics
• To review the presence, significance and management of hypothalamic-pituitary-adrenal axis function, including susceptibility to infections, in patients receiving corticosteroids for asthma

10:30 Asthma treatment and the HPA axis | Paul Greenberger
Learning Objectives:
• To review HPA axis suppression and its clinical significance in adults and children
• To describe methods for diagnosing HPA axis suppression
• To explain the implication on selection of treatment for asthma and allergic diseases

10:50 Asthma and endocrine disorders | Dennis Ledford
Learning Objectives:
• To describe associations between diabetes, obesity and asthma, and the special considerations in their management
• To describe associations between thyrotoxicosis and asthma and implications for treatment

11:10 Asthma co-morbidities in pregnancy | Harold Nelson
Learning Objectives:
• To provide an update on the relationship between asthma and pregnancy
• To review the management of asthma during pregnancy with special emphasis on safety of treatment

11:30 Question & Answer

SY9 Symposium: New concepts in severe asthma
Learning Objectives:
• To review new definitions of severe asthma (WHO; ERS/ATS Task Force on Severity and Control) and their clinical implications for the practitioner
• To introduce the concept of phenotyping of asthma and its role in clinical practice in adults and children
• To consider the potential of an understanding of phenotyping upon the design of new treatments and new strategies in asthma management
• To review current treatment approaches and treatment options in severe refractory asthma and potential new drugs in development and what they might offer

10:30 Asthma phenotypes: A clinically useful concept | Adnan Custovic
Learning Objective:
• To consider the potential of an understanding of phenotyping upon the design of new treatments and new strategies in asthma management

10:50 Defining and diagnosing severe asthma | Eric Bateman
Learning Objective:
• To review new definitions of severe asthma (WHO; ERS/ATS Task Force on Severity and Control) and their clinical implications for the practitioner

11:10 Small airway disease in asthma | Stephen Peters
Learning Objectives:
• To define small airway function in asthma
• To review pathophysiological alterations that are unique to small airway
• To assess therapies that are targeted to the small airway

11:30 Question & Answer
12:00 – 13:00

KN2  Keynote Lunch Symposium: Use of antimicrobials to treat acute exacerbations of chronic bronchitis, asthma and COPD
Learning Objectives:
• To explain the underlying triggers and pathomechanisms of acute exacerbations of chronic bronchitis, asthma and COPD
• To clarify the role of antibiotics in the management of acute exacerbations of chronic bronchitis, asthma and COPD
• To explain the evidence-based treatment strategies for acute exacerbations in chronic bronchitis, asthma and COPD
Speaker: Eric Bateman

13:00 – 14:00

Poster Session

14:00 – 16:00

PS4  Plenary: Psychological and societal dimensions of asthma
Learning Objectives:
• To highlight the links between the mind and body in asthma
• To identify the impact of psychological factors upon attitudes regarding compliance and the implications for treatment
• To describe the influence of socioeconomic factors on the prevalence and management of asthma
• To consider special behavioral and developmental issues affecting children with asthma

14:00 Developmental and behavioral problems in asthmatic children and adolescents  | Michael Blaiss
Learning Objectives:
• To review the impact of asthma on the physical and psychological development of children and their quality-of-life
• To consider the influence of these factors upon asthma management
• To review special problems in adolescents with asthma

14:25 Role of personality, stress and mood in asthma  | Eric Bateman
Learning Objectives:
• To review the role of personality type on the development and management of asthma
• To address the significance of mood, and other emotional factors, upon the management of asthma, and the resulting parallels with the management of other chronic diseases

14:50 Asthma as a public health concern  | Giovanni Viegi
Learning Objectives:
• To address the contribution of living environment and socio-economic status to the prevalence and burden of asthma
• To review the impact of access to care upon the natural history of asthma and the concept of a “poverty trap”
• To consider opportunities and methodologies for intervening in resource-poor settings

15:15 Asthma care in resource-poor settings  | Mario Sánchez-Borges
Learning Objectives:
• To review successful national and local health system interventions that address the care of asthma and allergies at the community level
• To consider different models and successful examples of care for asthma and respiratory allergies in resource-poor settings

15:40 Question & Answer
SY10 Symposium: Immunotherapy and immune modulators in asthma and allergic rhinitis

Learning Objectives:
• To explain the mechanisms of and indications for immunotherapy
• To review the available immunotherapy approaches
• To review when and how to use immunotherapy and assess its success

16:30 Subcutaneous immunotherapy | Harold Nelson

Learning Objectives:
• To review subcutaneous immunotherapy techniques and their risks and benefits
• To identify immune mechanisms related to benefits derived from immunotherapy
• To review data that suggests that immunotherapy in early life may alter asthma expression and severity

16:50 Sublingual immunotherapy for patients with allergic rhinitis and asthma | G. Walter Canonica

Learning Objectives:
• To review the technique of sublingual immunotherapy for types and doses of allergens administered
• To explain the risks and the benefits of sublingual immunotherapy
• To identify patient populations that would be appropriate targets for this type of therapy

17:10 Novel strategies and future directions in immunotherapy | Glenis Scadding

Learning Objectives:
• To address how to improve the effectiveness and safety of immunotherapy
• To review new therapeutic entities in trial
• To consider the implications of immunotherapy for the allergic march in children

17:30 Question & Answer

SY11 Symposium: Asthma and ocular allergy co-morbidity

Learning Objective:
• To show that coexistent allergic eye disease is common in asthma but frequently overlooked

16:30 Epidemiology and pathomechanisms of ocular allergy | Michael Blaiss

Learning Objectives:
• To describe the cellular, mediator and cytokine mechanisms of both acute and chronic allergic eye disease
• To explain how to connect mechanisms to prognosis and treatment

16:50 Asthma and rhinoconjunctivitis co-morbidity and quality-of-life | Fulvio Braido

Learning Objectives:
• To explain how allergic conjunctivitis can impact not only symptoms of asthma but also quality-of-life measures
• To review the concept of the upper and lower airways expressing allergic responses together

17:10 Treating the ocular component of allergic rhinoconjunctivitis | Sergio Bonini

Learning Objectives:
• To describe the treatment options, with guidelines for their use, of this condition in its various stages of severity and chronicity
• To explain in detail the “United Airways” concept

17:30 Question & Answer
16:30 – 18:00 (continued)

**SY12 Symposium: Asthma and COPD**

**Learning Objectives:**
- To provide insight into how disordered cell and molecular processes in these diseases can be used as diagnostic and prognostic tests
- To provide updates on new methods that help in diagnosis of lung diseases
- To review allergen avoidance strategies: Those that work and those that do not

**16:30 Biomarkers in the assessment of asthma and COPD** | *Louis-Philippe Boulet*

**Learning Objectives:**
- To provide insight into how disordered cell and molecular processes in these diseases can be used as diagnostic and prognostic tests
- To offer new knowledge about methods used to find biomarkers related to disease mechanisms
- To provide some examples of biomarkers that influence the stratification of these diseases

**16:50 Diagnosing and managing asthma and COPD** | *Neil Barnes*

**Learning Objectives:**
- To provide updates on new methods that help in diagnosis of lung diseases
- To show how treatments for these conditions can be tailored to individual patient needs
- To explain about the control of underlying disease processes and exacerbations

**17:10 Smoking cessation** | *Riccardo Polosa*

**Learning Objectives:**
- To explain how active and passive smoke exposure influences asthma and COPD
- To provide insight into different ways that people can be encouraged to quit smoking
- To identify how best to maintain non-smoking in a previously habitual smoker

**17:30 Allergen avoidance strategies to reduce morbidity in asthma** | *Adnan Custovic*

**Learning Objectives:**
- To review allergen avoidance strategies: Those that work and those that do not
- To review avoidance of drugs and selected domestic and occupational triggers
- To describe unusual forms of asthma
- To consider the role of vaccination against influenza and other specific and non-specific antibacterial measures

**17:50 Question & Answer**
### SCIENTIFIC PROGRAM—WEDNESDAY, 8 DECEMBER 2010

#### 8:00 – 9:30

<table>
<thead>
<tr>
<th>PS5</th>
<th>Plenary: Asthma and atopic eczema, food allergy, anaphylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td>• To explain the clinical presentation of atopic dermatitis and its management</td>
<td></td>
</tr>
<tr>
<td>• To present information regarding the natural history of food allergy</td>
<td></td>
</tr>
<tr>
<td>• To review the management of anaphylaxis in the asthmatic patient</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08:00</th>
<th>Atopic eczema and respiratory allergy</th>
<th>Adnan Custovic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To review the concept of the “atopic march”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To present information regarding similarities and differences in the allergic pathophysiologic response between the skin and the respiratory tract</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To explain the clinical presentation of atopic dermatitis and its management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08:25</th>
<th>Asthma and food allergy</th>
<th>Alessandro Fiocchi</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To review the definition of the term “food allergy”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To address the relationship between food allergy and managing asthma control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To review the natural history of food allergy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08:50</th>
<th>Outgrowing asthma</th>
<th>Carlos E. Baena-Cagnani</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objective:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To review the concept of outgrowing asthma in the adolescent years and the possible factors and mechanisms involved</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 09:15 | Question & Answer |

#### 9:30 – 10:30

**Poster Session**

#### 11:00 – 12:45

<table>
<thead>
<tr>
<th>SY13</th>
<th>Symposium: Asthma and concomitant chest diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td>• To provide insight into the pulmonary complications of chronic asthma</td>
<td></td>
</tr>
<tr>
<td>• To explain the investigational steps that need to be taken to exclude intrapulmonary complications</td>
<td></td>
</tr>
<tr>
<td>• To provide insight into approaches to prevention and treatment</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:00</th>
<th>Occupational rhinitis and asthma</th>
<th>Hae-Sim Park</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To consider guidelines for the diagnosis and management of occupational asthma and rhinitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To provide a discussion on the mechanisms of the disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:20</th>
<th>Asthma, cystic fibrosis and bronchiectasis</th>
<th>Neil Barnes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To review the role of allergy in cystic fibrosis and bronchiectasis and the development of asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To consider the role of allergy and asthma in the pathogenesis of bronchiectasis, including bronchopulmonary aspergillosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>11:40</th>
<th>Cough variant asthma</th>
<th>Pramod Kelker</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Learning Objectives:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To explain cough as a symptom of asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• To show how to recognize the entity of cough variant asthma and consider approaches to its diagnosis and management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 12:00 | Question & Answer |
### SY14 Symposium: Asthma and viral infections

**Learning Objectives:**
1. To review the contribution of viral respiratory tract infections to pre-school wheezing
2. To address the relative contribution of various respiratory tract pathogens in COPD disease exacerbations and relevant therapeutic approaches
3. To present data as to the relative importance of various non-viral triggering factors in disease management

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Early viral infections: Their role in the development of asthma</td>
<td>Robert Lemanske</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review the contribution of viral respiratory tract infections to pre-school wheezing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To explain the role of rhinovirus infections in asthma risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To compare and contrast RSV versus rhinovirus infections in early childhood and their impact on the development of childhood asthma</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>Managing the wheezing infant</td>
<td>Alessandro Fiocchi</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To describe the various wheezing phenotypes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review information regarding how to identify the likelihood of asthma developing in children who wheeze early in life</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To present data regarding whether early recognition and treatment of pre-school wheezing can prevent the development of asthma</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>Non-viral triggers of asthma exacerbation</td>
<td>Louis-Philippe Boulet</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review the factors that trigger exacerbations of asthma in addition to viruses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To present data as to the relative importance of various non viral triggering factors in disease management (both prevention and intervention)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To consider whether various triggering mechanisms induce different pathophysiologic changes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Question &amp; Answer</td>
<td></td>
</tr>
</tbody>
</table>

### SY15 Symposium: Asthma and chest co-morbidities in the Middle East

**Learning Objective:**
To provide an understanding of the impact of indoor pollutants on asthma and the asthma management strategies in the region

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Asthma and smoking</td>
<td>Mohammad Reza Masjedi</td>
</tr>
<tr>
<td></td>
<td>Learning Objective:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review the impact of smoking on asthma and to provide insight into the different ways that people are encouraged to quit smoking in the region</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>Asthma management strategies in the Middle East</td>
<td>Majdi Idris</td>
</tr>
<tr>
<td></td>
<td>Learning Objective:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review asthma management strategies in the region</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>Inhaled steroids and airway remodeling</td>
<td>Adel Wahadneh</td>
</tr>
<tr>
<td></td>
<td>Learning Objective:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review the therapeutic impact of inhaled steroids on airway remodeling</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Monoclonal antibodies in asthma therapy – Middle East perspective</td>
<td>Yehia El-Gamal</td>
</tr>
<tr>
<td></td>
<td>Learning Objective:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To review the role of monoclonal antibodies in asthma management in the region</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20</td>
<td>Question &amp; Answer</td>
<td></td>
</tr>
</tbody>
</table>
12:45 – 13:45

**KN3 Keynote Lunch Symposium: Asthma and immunotherapy – Past, present and future**

**Learning Objectives:**
- To review the history of the development of immunotherapy, its mechanisms and indications for immunotherapy
- To review the available immunotherapy approaches.
- Subcutaneous immunotherapy versus sublingual immunotherapy and the WAO Position Paper on Sublingual Immunotherapy

**Speaker:** G. Walter Canonica

13:45 – 16:00

**PS6 Plenary: Asthma and COPD - Present and future therapies**

**Learning Objectives:**
- To provide insight into new therapeutic targets for these diseases
- To consider how to manage these diseases in an ideal world
- To prepare for what may be on the horizon

**13:45 Novel therapies for asthma and COPD**

*Paul O’Byrne*

**Learning Objectives:**
- To consider whether asthma is a single disorder or different disorders
- To address why new treatments are needed
- To provide examples of new therapies

**14:10 Future use of biologics in asthma and allergy**

*Lanny Rosenwasser*

**Learning Objectives:**
- To explain what is a “biologic”
- To provide examples of their use in chronic asthma and COPD
- To describe possible side effects and short and long term benefits

**14:35 Anti-IgE treatment in severe asthma**

*Thomas B. Casale*

**Learning Objectives:**
- To explain the rationale behind IgE blockade
- To consider which patients benefit
- To address how to assess response

**15:00 Controversies in LABA**

*Stephen Peters*

**Learning Objectives:**
- To provide insight into adverse effects of LABAs and underlying mechanisms
- To consider what the current evidence adds up to
- To encourage asking the question: Should we be worried: If so, about what aspects?

**15:25 Question & Answer**
CALL FOR ABSTRACTS

Abstract Submission is Open!

Abstract Submission Deadline: 16 July 2010

The World Allergy Organization invites you to submit abstracts for review for Poster Presentation.

Abstracts will be accepted online only. To submit an abstract, please visit our website: [www.worldallergy.org/2010Dubai](http://www.worldallergy.org/2010Dubai).

ABSTRACT SUBMISSION GUIDELINES:

- The abstract must be written and presented in English.
- Abstracts must contain original data and meet international ethical standards.
- A maximum of three abstracts may be submitted by the same Presenting Author.
- An identical abstract cannot be submitted twice to different categories.
- Use a maximum of 2,500 characters (approximately 350 words), including blank spaces, for the abstract text.
- The abstract title must begin with a capital letter and be followed by lower case letters. Use capital and lower case letters as appropriate for abbreviations in title.
- References (maximum of 2) can be included in the body of the text.
- The abstract title and the author(s) or names of institutions are not to be included in the abstract text.
- Credits or the authors’ academic degrees or grant support are not to be included in the abstract.
- Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording the first time it appears in the body of the text.
- Non-proprietary (generic) names of drugs, written in lower case, are required the first time a drug is mentioned.
- Trade names are not allowed.

In order to make the abstract as informative as possible, please include a brief statement of the purpose of the study, the method used, the results observed, and the conclusions based upon the results. It is inadequate to state “The results will be discussed” or “The data will be presented”. We kindly ask you to subtitle the paragraphs in bold format in the following order: Background, Method, Results, and Conclusion.

ABSTRACTS MAY BE SUBMITTED IN THE FOLLOWING CATEGORIES:

- Airborne allergens and air pollution
- Allergens: Biology
- Allergens: Diagnosis
- Allergic immune response
- Allergy and tobacco smoke and other environmental factors
- Allergy prevention and risk factors
- Anaphylaxis
- Asthma: Education
- Asthma: Epidemiology
- Asthma: Management
- Asthma: Mechanisms
- Atopic dermatitis and other skin conditions: Management
- Atopic dermatitis and other skin conditions: Mechanisms
- Autoimmunity and immunodeficiency
- Contact allergic dermatitis
- Diagnosis and management of rhinitis
- Drug allergy: Clinical aspects
- Drug allergy: Mechanisms
- Eosinophil and mast cell associated disorders
- Epidemiology of rhinitis and conjunctivitis
- Food allergy: Diagnosis and management
- Food allergy: Epidemiology
- Food allergy: Mechanisms
- Hymenoptera allergy and latex allergy
- Immunogenetics and immunogenomics
- Immunotherapy (clinics)
- Immunotherapy mechanisms
- Immunotherapy vaccines
- Infection and allergy
- Innate and adaptive immunity
- Laboratory tests for allergy
- Miscellaneous
- Molecular allergology
- Occupational allergy
- Occupational asthma and rhinitis
- Ocular allergy
- Pediatric allergy
- Pediatric asthma and rhinitis
- Pediatric: Epidemiology
- Sinusitis and nasal polypos
- Sports & allergy and asthma
- Training and education
- Urticaria and angioedema
CALL FOR ABSTRACTS (CONTINUED)

ABSTRACT PRESENTATION
It is the author’s responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as submitted by the author. Abstracts will be rejected if they contain no data or if the English is unacceptable. All Presenting Authors will receive detailed guidelines when their abstract(s) have been accepted.

Accepted abstracts selected by expert reviewers will be presented as poster presentations.

Poster Sessions:
All posters will be presented in guided poster discussion sessions. The Presenting Authors will stand by their posters during the entire Poster Session and should be prepared to discuss their research with delegates.

Attendance of presenters:
WAO cannot guarantee that those Presenting Authors who do not show up during the session will be accepted for abstract presentations at future WAO meetings.

Updates and changes to your abstract:
Changes to abstracts are accepted only through the submission deadline and by using only the abstract submission website.

NOTIFICATION OF ACCEPTANCE
Notification of acceptance / rejection will be sent by the end of September 2010. The Presenting Author will receive all correspondence concerning the abstract. The Presenting Author is responsible for informing all other authors of the status of the abstract.

REGISTRATION OF PRESENTERS
All poster presenters must be registered for the Conference by 31 October 2010 or their abstract will be automatically withdrawn.

PUBLICATION OF ABSTRACTS
Accepted abstracts will be published in the Final Program, which will be distributed onsite during the Conference.

For submission support, please contact the WAO Secretariat at WISC2010abstracts@worldallergy.org.
REGISTRATION

Registration is Open!
Registration queries: WISC2010registration@worldallergy.org

REGISTRATION FEES IN US DOLLARS

<table>
<thead>
<tr>
<th></th>
<th>Early Registration 14 April – 16 July</th>
<th>Late Registration 17 July – 31 October</th>
<th>Onsite Registration 4 – 8 December</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegates</td>
<td>460 USD</td>
<td>510 USD</td>
<td>610 USD</td>
</tr>
<tr>
<td>Nurses / Students</td>
<td>250 USD</td>
<td>250 USD</td>
<td>350 USD</td>
</tr>
<tr>
<td>Accompanying Persons</td>
<td>150 USD</td>
<td>150 USD</td>
<td>250 USD</td>
</tr>
</tbody>
</table>

REGISTRATION FOR DELEGATES, NURSES AND STUDENTS INCLUDES:
- Postgraduate Courses on 5 December
- Admission to all scientific sessions
- Keynote Lunch Symposia
- Conference bag and meeting materials
- Access to Exhibition Hall
- Certificate of attendance
- Invitation to Opening Ceremony and Welcome Reception
- Junior Networking Session on 6 December

REGISTRATION FOR ACCOMPANYING PERSONS INCLUDES:
- Access to Exhibition Hall
- Invitation to Opening Ceremony and Welcome Reception
- Keynote Lunch Symposia

Registration does not include admission to scientific sessions or conference bag and meeting materials

NURSE REGISTRATION
Nurses are eligible to receive the discounted registration rate. Please submit proof of certification with your registration.

STUDENT REGISTRATION
Medical students and trainees are eligible to receive the discounted registration rate. Please submit proof of enrollment, signed by the Head of the Department, to register at the discounted rate.

PAYMENT
Registration payment should be made by credit card (Visa, MasterCard or American Express). For additional payment options, please send your inquiry to WISC2010registration@worldallergy.org.

ONSITE REGISTRATION
After 31 October 2010, only onsite registration will be available. Onsite registration will begin on 4 December 2010. Please check the conference website, [www.worldallergy.org/2010Dubai](http://www.worldallergy.org/2010Dubai), for specific registration hours and locations.

CANCELLATION AND REFUNDS
All notification of cancellations must be sent in writing to the WAO Secretariat at: [WISC2010registration@worldallergy.org](mailto:WISC2010registration@worldallergy.org)

REFUND POLICY
Before 16 July 2010
100% Refund (with 75 USD handling fee charge)
From 17 July to 31 October 2010
50% Refund
After 31 October 2010
No Refund
SOCIAL PROGRAM

Name badges are strictly required for all Social Events.

OPENING CEREMONY AND WELCOME RECEPTION
Sunday, 5 December 2010
19:00 – 22:00
Dubai International Convention and Exhibition Centre
Join fellow delegates and the WAO leadership in the Plenary Hall for the Opening Ceremony to launch the conference. Following the Opening Ceremony, we’ll move to a hosted reception in the Exhibit Hall featuring hors d’oeuvres, cocktails and the opportunity to network with colleagues and friends.
*Included in registration fee for delegates, nurses, students and accompanying persons.*

POSTER VIEWING AND NETWORKING SESSION WITH FACULTY AND THE WAO LEADERSHIP
Monday, 6 December 2010
17:00 – 18:30
Dubai International Convention and Exhibition Centre
Junior delegates will have the opportunity to discuss and view posters in an informal setting, as well as network with Conference faculty and the WAO Leadership. Light refreshments will be served.
*Included in registration fee for delegates, nurses, and students.*

OPTIONAL TOURS

To book your tour online, please visit www.worldallergy.org/2010Dubai/tours.php.

MCI Middle East, the local Professional Congress Organizer, will be handling all optional tours for the 2010 WAO International Scientific Conference. Please email wisc2010@mci-group.com for more information or to register for tours.

<table>
<thead>
<tr>
<th>Sunday, 5 December</th>
<th>Monday, 6 December</th>
<th>Tuesday, 7 December</th>
<th>Wednesday, 8 December</th>
</tr>
</thead>
<tbody>
<tr>
<td>City of Contrasts – Sharjah Cultural Tour 9:00 – 13:00</td>
<td>Modern “Do Buy” Shopping Tour 12:00-16:00</td>
<td>City of Contrasts – Sharjah Cultural Tour 10:30 – 14:30</td>
<td>Camel Riding &amp; Sand Boarding Safari 10:30 – 14:30</td>
</tr>
<tr>
<td>City of Merchants – Dubai Orientation Tour 14:30-18:00</td>
<td>City of Merchants – Dubai Orientation Tour 14:30-18:00</td>
<td>Camel Riding &amp; Sand Boarding Safari 10:30 – 14:30</td>
<td>City of Merchants – Dubai Orientation Tour 14:30 – 18:00</td>
</tr>
<tr>
<td>High Tea at Burj Al Arab – The Arabian Tower 15:00 – 17:00</td>
<td>Modern “Do Buy” Shopping Tour 12:00-16:00</td>
<td></td>
<td>Sunset Cruise 16:00-18:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>City of Merchants – Dubai Orientation Tour 14:30 – 18:00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Desert Safari with BBQ Dinner 15:00-20:00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sunset Cruise 16:00-18:00</td>
</tr>
</tbody>
</table>

**Important Tour Information:**
1. Please sign up for your sightseeing tours by emailing wisc2010@mci-group.com. Tours are optional and limited; early booking is advisable and reservations will be taken on first-come, first-served basis.
2. All tours are conducted in English.
3. Tour duration and dates of operation are subject to change. The tour can be cancelled if a minimum number of participants is not achieved. MCI will confirm the operation of tours 1 month prior to conference date.
4. For all tours, the pick-up and drop-off point is the Dubai International Convention and Exhibition Centre. Kindly report to the pick-up point 15 minutes prior to the start of the tour.
5. For post-convention tours, please email wisc2010@mci-group.com.
CITY OF CONTRASTS - SHARJAH CULTURAL TOUR
35 USD Per Person – 10 Person Minimum
Sharjah was crowned by UNESCO Cultural Capital of the Arab World in 1998. With a reputation for artistic excellence, the emirate boasts over 15 museums, an aquarium and a center for Arabian wildlife.

Anyone who has an interest in local history, culture and architecture will enjoy exploring Sharjah’s old city. A visit to Souq Al Arsah, Sharjah’s oldest market, is a must.

The next stop is the Sharjah Heritage Museum, beginning a journey of discovery through Sharjah’s rich and diverse heritage, with handcrafted works of art and objects that date back to a time when local people relied solely on fishing and pearling. Discover the traditional skills and crafts relating to jewelry, costumes, and herbal medicines, music and folklore.

CITY OF MERCHANTS - DUBAI ORIENTATION TOUR
35 USD Per Person – 10 Person Minimum
Experience the historic sites and lively multi-ethnic life of Dubai. From the famous Burj Al Arab to the Gold souk, you’ll see all the famous sights of Dubai on this leisurely tour.

Your excursion begins with a drive on Sheikh Zayed Road to view the city's skyscrapers, with a photo stop at Dubai’s most famous landmark and tallest tower in the world - Burj Khalifa. The tour proceeds to Jumeirah, where we can witness the world-renowned luxury hotel Burj Al Arab – with the unique billowing sail design. The hotel is a must-see for all visitors to Dubai.

See some of the palaces of the Royal Family and residential areas, with a stop at the eminent Jumeirah Mosque and a drive by the palace of the ruler of Dubai. We then proceed to Al Bastakiya, Dubai’s atmospheric old quarter by the Creek. Then it’s all aboard the Abra (water taxi) to cross the Creek to the spice souk. You’ll then have time to shop in another famous Dubai landmark, the glittering gold souk.

DESERt SAFARI WITH BBQ DINNER
90 USD Per Person – 6 Person Minimum
This tour departs in the afternoon by four-wheel drive vehicles across the desert of Dubai with several photo-stops. A camel farm is the first destination of this exciting dune drive. The drive continues across the desert, stopping to watch the beautiful sunset before reaching the campsite where you have the opportunity for a camel ride, sand boarding and trying out a henna design on your hands or feet. Enjoy a delicious barbecue dinner and shisha (the famous Arabic water pipe). Before returning to Dubai, watch our belly dancer performing her show around the campfire by starlight.

MODERN “DO BUY” SHOPPING TOUR
35 USD Per Person – 10 Person Minimum
Dubai is a shopper’s paradise offering an endless choice to suit every budget. Our shopping tour will take you to the following places.

Souk Madinat Jumeirah - The souk is a colorful and vibrant market or part of a market in an Arabian city. Lively trading culture, animated and interactive - this defines Souk Madinat Jumeirah.

Dubai Mall - the region’s premier shopping, lifestyle and entertainment destination. The Dubai Mall is a place where outdoor brunch can be followed by the delights of the big screen and a 21st century gold souk is set off against a world class aquarium. When was the last time you could shop designer stores under the watchful eye of a giant sea turtle? Step inside The Dubai Mall and experience a place like no other.

HIGH TEA AT BURJ AL ARAB - THE ARABIAN TOWER
90 USD Per Person – 10 Person Minimum
Enjoy a luxurious afternoon tea in Dubai’s icon, Burj Al Arab. Designed to resemble a billowing sail, the hotel soars to a height of 321 meters, dominating the Dubai coastline. This all-suite hotel reflects the finest in architecture that the world has to offer for an unforgettable afternoon.

Dress Code for High Tea: Smart casual; please refrain from wearing: jeans, T-shirts (must wear collared shirt), shorts, sandals (not applicable for ladies), sporting shoes / trainers.
OPTIONAL TOURS (CONTINUED)

SUNSET CRUISE
45 USD Per Person – 10 Person Minimum
What could be more enchanting than to marvel at the sunset aboard a dhow as it slips silently along Dubai Creek? Your cruise aboard traditional wooden vessels offers an intriguingly different view of this amazing city – a portrait of the true character of Dubai, the intertwining of the traditional and modern.

See old wooden dhows, luxury yachts and spectacular modern architecture. Offering a selection of two select beverages, this tour reflects a delicious taste of true Arabian hospitality.

CAMEL RIDING & SANDBOARDING SAFARI
75 USD Per Person – 6 Person Minimum
Travel with our experienced safari guides in four-wheel drive vehicles to the desert for a thrilling journey over the rolling dunes.

After an exhilarating drive, enjoy a camel ride just like the nomadic Bedouin have done for centuries. Abandon tradition for a breathtaking mode of transport: strapping on a sand board for an exhilarating ride down the steep-sided dunes to the valley floor below.

ACCOMMODATION

Accommodation Reservation Deadline: 1 September 2010
To book your accommodation online, please visit: www.worldallergy.org/2010dubai/accommodation.php
For queries, please contact MCI Middle East at wisc2010@mci-group.com.

HOTEL RATES AND CONDITIONS

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Room Type</th>
<th>Single Room/night</th>
<th>Double Room/night</th>
<th>Buffet Breakfast</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 Star Hotels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grand Hyatt Dubai</td>
<td>Deluxe Room</td>
<td>290.70 USD</td>
<td>324.90 USD</td>
<td>Included</td>
</tr>
<tr>
<td>Fairmont Dubai</td>
<td>Regular Room</td>
<td>290.70 USD</td>
<td>324.90 USD</td>
<td>Included</td>
</tr>
<tr>
<td></td>
<td>Gold Room</td>
<td>376.20 USD</td>
<td>410.40 USD</td>
<td>Included</td>
</tr>
<tr>
<td>Shangri-La Dubai</td>
<td>Deluxe Room</td>
<td>273.60 USD</td>
<td>307.80 USD</td>
<td>Not Included</td>
</tr>
<tr>
<td>4 Star Hotels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Towers Rotana</td>
<td>Standard Room</td>
<td>156.75 USD</td>
<td>171.00 USD</td>
<td>Included</td>
</tr>
<tr>
<td>Rose Rahyaan by Rotana</td>
<td>Standard Room</td>
<td>121.13 USD</td>
<td>135.38 USD</td>
<td>Included</td>
</tr>
<tr>
<td>Novotel World Trade Centre</td>
<td>Standard Room</td>
<td>213.75 USD</td>
<td>228.00 USD</td>
<td></td>
</tr>
<tr>
<td>3 Star Hotels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibis World Trade Centre</td>
<td>Standard Room</td>
<td>85.50 USD</td>
<td>85.50 USD</td>
<td>Included</td>
</tr>
</tbody>
</table>

RESERVATION AND PAYMENTS
Reservations will be handled on a first-come, first-served basis. In the event your preferred hotel is fully booked, the MCI Dubai reserves the right, after consultation with the participant, to book another hotel. To guarantee a hotel reservation, the whole stay of accommodation will be charged as a deposit fee at the time of registration to the delegate’s credit card. Guests are responsible for payment of all additional charges at checkout. All listed hotel rates include service charge and municipality fees.

Please note that the deadline for guaranteed room reservations is 1 September 2010. Requests for room reservations after this deadline can only be handled upon availability and with credit card guarantee.

CHANGE OF HOTEL BOOKINGS
All changes to hotel reservations will be performed by MCI Dubai. All changes must be requested in writing to MCI Dubai at wisc2010@mci-group.com.

CHECK-IN /CHECK-OUT TIME
Hotel check-in time is 15.00 hrs or later. If arriving after 18.00 hrs, please notify MCI Dubai in advance. Check-out time is between 11.00 and 12.00 hrs (depending on the hotel). In order to guarantee your room availability for an early check-in or late check-out, an additional night reservation is strongly recommended.

CANCELLATION TERMS AND CONDITIONS
We regret that no refunds can be made after the 1st September 2010 deadline. Please contact MCI Dubai in case of questions or alterations and cancellations.
GENERAL INFORMATION

DUBAI
The 1st WAO International Scientific Conference will take place in Dubai, the second largest of the seven emirates that make up the United Arab Emirates.

Located on the southern shore of the beautiful Arabian Gulf, Dubai is a city-state, replete with clean, sandy beaches and clear, blue-green waters. It has an ancient Islamic heritage that survives amidst the skyscrapers and highways of a modern, cosmopolitan city of almost 1.4 million people. This ‘Pearl of the Arabian Gulf,’ concentrated mainly on its exquisite creek, the finest natural shelter in 1600km (1000 miles) of coastline, ranks as the United Arab Emirates’ most important port and commercial center.

With great underwater visibility and lots of sea life, snorkeling is a popular pastime in Dubai, as is quad biking in the desert, camel riding, deep sea fishing and windsurfing. With a number of challenging golf courses, some with gorgeous views of the Creek, and the desert, there is plenty of choice in Dubai for the avid golfer.

With over five large shopping malls in Dubai, there is a large variety of shops to choose from. Shoppers can find the best in designer labels and some fantastic bargains. There are local souks for those who do not wish to go to the malls, which offer local merchandise ranging from clothes and fabrics to regional food and fruit, woodcarvings and handicrafts.

CLIMATE AND DRESS
Dubai has a sub-tropical, arid climate. Sunny, blue skies can be expected most of the year. Rainfall is infrequent and irregular, falling mainly in winter. Temperatures range from a low of about 10.5°C / 50°F to a high of 48°C / 118°F. Dress for the conference is business casual.

CURRENCY
The currency in Dubai is the UAE Dirham (AED). Notes are in denominations of AED 1,000, 500, 200, 100, 50, 20, 10 and 5. Coins are in denominations of AED 1, and 50, 25, 10 and 5 fils.

Exchange rates, as of May 2010:

£1.00 = AED 5.30  
$1.00 = AED 3.67  
€1.00 = AED 4.55

ELECTRICITY
The voltage in United Arab Emirates is 220 / 240 volts A / C at 50 cycles.

EXHIBITION
A commercial exhibition will take place on the following dates and times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 5 December</td>
<td>20:00 - 22:00</td>
</tr>
<tr>
<td>Monday, 6 December</td>
<td>9:00 - 18:30</td>
</tr>
<tr>
<td>Tuesday, 7 December</td>
<td>9:00 - 16:30</td>
</tr>
<tr>
<td>Wednesday, 8 December</td>
<td>9:00 - 13:30</td>
</tr>
</tbody>
</table>

If you would like information on exhibiting at the WAO International Scientific Conference, please contact the WAO secretariat at +1 414 276 1791 or via email at WISC2010exhibition@worldallergy.org.

INSURANCE / LIABILITIES AND DISCLAIMER
WAO will not be held liable for personal injuries or for loss or damage to property incurred by participants or guests at the WAO International Scientific Conference, including those participating in tours and social events. Participants and guests are encouraged to purchase insurance to cover loss incurred in the event of cancellation, medical expenses or damage to or loss of personal effects when traveling outside of their own countries.

WAO cannot be held liable for any hindrance or disruption of the International Scientific Conference proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control. Registration of a participant implies acceptance of this condition.

The materials presented at this continuing medical education activity are made available for educational purposes only. The materials are not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement, or opinion of the faculty that may be helpful to others who face similar situations.

LANGUAGE
The official language of the conference is English. Arabic is the official language of Dubai, although English, Malayalam, Hindi, Urdu, Bengali, Tamil, Persian, Tagalog, Chinese and other languages are also spoken.

MEALS
Coffee breaks on 5, 6, 7 and 8 December and lunches on 6.7 and 8 December are included in the registration fee for delegates, nurses, students and accompanying persons.

NAME BADGES
Official name badges will be provided onsite with other Conference materials. Name badges will be required for admission to all Conference and Poster Sessions, and the Exhibition Hall. Name substitutions may be requested by contacting the WAO Secretariat until 31 October 2010.

NO SMOKING POLICY
Smoking is not permitted during any meeting activity or event.
PARTNERSHIP OPPORTUNITIES
Partnership Opportunities are currently available for the 2010 WAO International Scientific Conference. Partnership provides visibility for an organization and shows support for the field of allergy, asthma and immunology, as well as the ongoing initiatives of WAO and the 2010 WAO International Scientific Conference. Partnership opportunities begin at 2,000 USD and can be tailored to meet individual needs. Packages are also available for a two-year commitment to include the 2011 World Allergy Congress in Cancún, México. Please contact the WAO secretariat at +1 414 276 1791 or via email at WISC2010exhibition@worldallergy.org for a copy of the Partnership Opportunities and Exhibitor Prospectus or to discuss options.

POSTER SESSIONS
Non-Competing Poster Sessions:
Monday, 6 December  17:00 – 18:30
Tuesday, 7 December  13:00 – 14:00
Wednesday, 8 December  9:30 – 10:30
Accepted abstracts will be presented during Poster Sessions. Presenting Authors will stand with their posters, answer questions and discuss their research.

QUESTIONS
For any questions regarding the 2010 WAO International Scientific Conference, please contact the WAO Secretariat at +1 414 276 1791 or via email at WISC2010@worldallergy.org.

SPECIAL NEEDS
If you require any specific accommodation to attend this Conference, please contact the WAO Secretariat at +1 414 276 1791 or WISC2010@worldallergy.org.

TELEPHONE
The country code for the United Arab Emirates is 971. The city code for Dubai is 4.

TRAVEL
The city is served by Dubai International Airport (DXB)—host to the world's largest duty free shopping area—situated in the central north part of the city. Dubai International Airport provides regular flights to and from the UK, Australia, America, Asia and Europe. More than 80 airlines take advantage of Dubai's open skies policy, and operate to and from Dubai International Airport to more than 130 destinations, making it one of the world's busiest airports.

VENUE
The venue for the Conference will be the Dubai International Convention and Exhibition Centre (DICEC). The DICEC offers world class exhibition and convention facilities and is centrally located.

VISAS
Nationals of the following countries do not require Visas to enter the UAE:

Andorra  Germany  Malaysia  Spain
Australia  Greece  Monaco  Sweden
Austria  Hong Kong  Netherlands  Switzerland
Belgium  Iceland  New Zealand  UK
Brunei  Ireland  Norway  USA
Canada  Italy  Portugal  Vatican
Denmark  Japan  San Marino
Finland  Liechtenstein  Singapore
France  Luxembourg  South Korea

For more information and assistance on obtaining a visa, please contact MCI Middle East, the local Professional Congress Organizer, at wisc2010@mci-group.com.
EXHIBITORS
LG Life Sciences, LTD.
Omron

IMPORTANT DATES

16 July 2010
Abstract Submission Deadline
16 July 2010
Early Registration Deadline
1 September 2010
Accommodation Reservation Deadline
31 October 2010
Late Registration Deadline
4 December 2010
Onsite Registration Begins
5-8 December 2010
1st WAO International Scientific Conference

General Inquiries
WISC2010@worldallergy.org
Registration
WISC2010registration@worldallergy.org
Abstracts
WISC2010abstracts@worldallergy.org
Exhibition
WISC2010exhibition@worldallergy.org

World Allergy Organization
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Phone: +1 414 276 1791
Fax: +1 414 276 3349

www.worldallergy.org/2010Dubai